The Generic Pharmaceuticals Association on Tuesday (Dec. 9) released compromise language it crafted with the Biotechnology Industry Organization for states considering legislation in 2015 requiring prescribers be notified when pharmacists substitute biosimilars deemed interchangeable with the original biologics, with the compromise stating that a pharmacist may communicate the substitution via interoperable electronic health records or electronic prescribing technology. The compromise language is similar to one reached on a Massachusetts law passed over the summer that both GPhA and the BIO...